Synthesis of 2H‐ and 13C‐labelled sunitinib and its primary metabolite |
| |
| Authors: | Paul W. Elsinghorst Michael Gütschow |
| |
| Affiliation: | Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, An der Immenburg 4, 53121 Bonn, Germany |
| |
| Abstract: | Sunitinib (Sutent®, Pfizer) was approved in 2006 for the treatment of gastrointestinal and renal cancer. Isotope‐labelled derivatives have already been prepared for PET and ADME radiography. The preparation of 13C‐ and 2H‐labelled internal standards of sunitinib (SU11248) and its primary metabolite (SU12662) for LC‐MS analysis of human blood samples is presented. Copyright © 2009 John Wiley & Sons, Ltd. |
| |
| Keywords: | sunitinib carbon‐13 deuterium SU11248 SU12662 |
|
|
